{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T05:52:00Z","timestamp":1791525120276,"version":"4.3.4"},"reference-count":20,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T00:00:00Z","timestamp":1791504000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Ulcerative colitis (UC) is reported with medications from different therapeutic classes. We examined these reporting associations together with recorded clinical context and tested whether experimental cytokine-blockade signatures align with human UC mucosal expression.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>FAERS reports from 2004Q1\u20132024Q4 were restricted to health professionals and primary-suspect medications. Ten previously identified candidates were evaluated using unique report\u2013generic counts, reporting odds ratios (RORs), proportional reporting ratios, and a supportive Bayesian information component. Sensitivity analysis excluded complete reports recording UC as an indication. Directional signatures from five antibody-versus-isotype contrasts in a 42-sample mouse colitis study were scored in two external human cohorts (87 UC\/21 controls and 74 active UC\/11 controls), using 12,109 common one-to-one orthologs. Ten primary score comparisons underwent joint Benjamini\u2013Hochberg correction.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Among 7,300,798 eligible FAERS reports, 11,352 included UC. Eight candidates met the specified reporting criteria; seven retained support after UC-indication exclusion. Secukinumab and isotretinoin had 204 and 130 UC reports, with RORs of 4.49 (95% CI 3.90\u20135.16) and 3.79 (3.19\u20134.51). Valganciclovir decreased from nine to three reports after exclusion and became imprecise. In human mucosa, experiment-2 IL-17A and IL-17RA blockade signatures scored lower in UC in both cohorts; experiment-1 IL-17RA showed a positive difference in only one cohort. IL-23p19 and IL-12\/23p40 blockade signatures scored lower in UC in both cohorts. These patterns persisted across the planned signature-size sensitivity analysis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Event-centered analysis differentiated reporting associations by their indication context. External experimental and patient data did not support a uniform UC-like transcriptional pattern following IL-17 blockade, refining the mechanistic interpretation of the reporting signals. The findings identify priorities for drug-specific clinical investigation without estimating incidence or establishing causality.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fimmu.2026.1827266","type":"journal-article","created":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T05:33:29Z","timestamp":1791524009000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Ulcerative colitis reporting across medications: FAERS analysis and cross-species transcriptomic triangulation"],"prefix":"10.3389","volume":"17","author":[{"given":"Huan","family":"Long","sequence":"first","affiliation":[{"name":"Department of Emergency, Ji\u2019an Central People\u2019s Hospital, Jizhou District","place":["Ji\u2019an, Jiangxi, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caihua","family":"Duan","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Ji\u2019an Central People\u2019s Hospital, Jizhou District","place":["Ji\u2019an, Jiangxi, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiusi","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Gastrointestinal Surgery, Ji\u2019an Central People\u2019s Hospital, Jizhou District","place":["Ji\u2019an, Jiangxi, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nanxi","family":"Xiao","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Ji\u2019an Central People\u2019s Hospital, Jizhou District","place":["Ji\u2019an, Jiangxi, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiang","family":"Huang","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Ji\u2019an Central People\u2019s Hospital, Jizhou District","place":["Ji\u2019an, Jiangxi, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huilei","family":"Zeng","sequence":"additional","affiliation":[{"name":"Department of Emergency, Ji\u2019an Central People\u2019s Hospital, Jizhou District","place":["Ji\u2019an, Jiangxi, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenling","family":"Gao","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Ji\u2019an Central People\u2019s Hospital, Jizhou District","place":["Ji\u2019an, Jiangxi, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yao","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Emergency, Ji\u2019an Central People\u2019s Hospital, Jizhou District","place":["Ji\u2019an, Jiangxi, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,10,9]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"716","DOI":"10.1001\/jama.2023.23814","article-title":"What is ulcerative colitis","volume":"331","author":"Voelker","year":"2024","journal-title":"JAMA"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2020.04.069","article-title":"Drug-induced colitis","volume":"19","author":"Hamdeh","year":"2021","journal-title":"Clin Gastroenterol Hepatol"},{"key":"B3","unstructured":"Fda Adverse Event Monitoring System Public Dashboard\n          \n          2026"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2015.08.019","article-title":"Differential roles for interleukin-23 and interleukin-17 in intestinal immunoregulation","volume":"43","author":"Maxwell","year":"2015","journal-title":"Immunity"},{"key":"B5","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1097\/MPG.0000000000001898","article-title":"Molecular comparison of adult and pediatric ulcerative colitis indicates broad similarity of molecular pathways in disease tissue","volume":"67","author":"Li","year":"2018","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1097\/MIB.0000000000001246","article-title":"Genetic and transcriptomic bases of intestinal epithelial barrier dysfunction in inflammatory bowel disease","volume":"23","author":"Vancamelbeke","year":"2017","journal-title":"Inflammation Bowel Dis"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1002\/pds.677","article-title":"Use of proportional reporting ratios (PRRs) for signal generation from spontaneous adverse drug reaction reports","volume":"10","author":"Evans","year":"2001","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1007\/s002280050466","article-title":"A Bayesian neural network method for adverse drug reaction signal generation","volume":"54","author":"Bate","year":"1998","journal-title":"Eur J Clin Pharmacol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1002\/pds.771","article-title":"Practical pharmacovigilance analysis strategies","volume":"12","author":"Gould","year":"2003","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"B10","unstructured":"Mouse\u2013Human Homology Sequence Report (HOM_Mousehumansequence.Rpt)\n          \n          2026"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gkv007","article-title":"limma powers differential expression analyses for RNA-sequencing and microarray studies","volume":"43","author":"Ritchie","year":"2015","journal-title":"Nucleic Acids Res"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2011-301668","article-title":"Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn's disease: unexpected results of a randomised, double-blind placebo-controlled trial","volume":"61","author":"Hueber","year":"2012","journal-title":"Gut"},{"key":"B13","unstructured":"BIMZELX bimekizumab-bkzx prescribing information\n          \n          2024"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2023.01.014","article-title":"A propensity score matched cohort study identifying an association of acne, but not oral antibiotic or isotretinoin use, with risk of incident inflammatory bowel disease","volume":"88","author":"Taylor","year":"2023","journal-title":"J Am Acad Dermatol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2022.12.015","article-title":"Isotretinoin and the risk of inflammatory bowel disease and irritable bowel syndrome: A large-scale global study","volume":"88","author":"Kridin","year":"2023","journal-title":"J Am Acad Dermatol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.4103\/ijd.ijd_644_23","article-title":"Association between isotretinoin exposure and inflammatory bowel disease: A nationwide case-control study in South Korea","volume":"69","author":"Hyeong","year":"2024","journal-title":"Indian J Dermatol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2025.1494467","article-title":"Colopathy associated with pentosan polysulfate use","volume":"16","author":"Jung","year":"2025","journal-title":"Front Pharmacol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.14309\/ajg.0000000000002137","article-title":"Pentosan polysulfate-associated dysplasia in patients with inflammatory bowel disease: A case series","volume":"118","author":"Anderson","year":"2023","journal-title":"Am J Gastroenterol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1093\/ecco-jcc\/jjag071","article-title":"ECCO guidelines on the prevention, diagnosis, and management of infections in inflammatory bowel disease","volume":"20","author":"Yanai","year":"2026","journal-title":"J Crohns Colitis"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1159\/000525012","article-title":"Severe inflammatory colitis related to encorafenib and binimetinib following immune checkpoint inhibitor therapy","volume":"16","author":"Issac","year":"2022","journal-title":"Case Rep Gastroenterol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1827266\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T05:33:30Z","timestamp":1791524010000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1827266\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,9]]},"references-count":20,"alternative-id":["10.3389\/fimmu.2026.1827266"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1827266","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,9]]},"article-number":"1827266"}}